JE
CRSP icon

Jacobs Equity’s CRISPR Therapeutics CRSP Stock Holding History

Jacobs Equity’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$800K Buy
14,675
+3,085
+27% +$163K 0.55% 56
2026
Q1 		$551K Sell
11,590
-500
-4% -$26.4K 0.49% 55
2025
Q4 		$634K Buy
+12,090
New +$724K 0.61% 49

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jacobs Equity's CRSP Position: Q2 2026 in Review

Jacobs Equity increased its CRISPR Therapeutics (CRSP) stake by 27% in Q2 2026, buying an estimated $163K and bringing the position to 14,675 shares worth $800K. The position accounts for 0.55% of the portfolio, ranked #56.

Jacobs Equity first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Jacobs Equity held 14,675 shares of CRISPR Therapeutics worth $800K as of Q2 2026.
  • Jacobs Equity bought 3,085 CRISPR Therapeutics shares in Q2 2026, an estimated $163K.
  • CRISPR Therapeutics made up 0.55% of Jacobs Equity's portfolio in Q2 2026, its #56 holding.
  • Jacobs Equity first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Jacobs Equity's 13F filing for Q2 2026, filed 17 Aug 2026.